EVISTA Film-coated tablet Ref.[8052] Active ingredients: Raloxifene

Source: European Medicines Agency (EU)  Revision Year: 2022  Publisher: SUBSTIPHARM, 24 rue Erlanger, 75016 Paris, France

Therapeutic indications

Evista is indicated for the treatment and prevention of osteoporosis in postmenopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.

When determining the choice of Evista or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5.1).

Posology and method of administration

Posology

The recommended dose is one tablet daily by oral administration, which may be taken at any time of the day without regard to meals. Due to the nature of this disease process, Evista is intended for long term use.

Generally calcium and vitamin D supplements are advised in women with a low dietary intake.

Elderly

No dose adjustment is necessary for the elderly.

Renal impairment

Evista should not be used in patients with severe renal impairment (see section 4.3). In patients with moderate and mild renal impairment, Evista should be used with caution.

Hepatic impairment

Evista should not be used in patients with hepatic impairment (see section 4.3 and 4.4).

Paediatric population

Evista should not be used in children of any age. There is no relevant use of Evista in the paediatric population.

Overdose

In some clinical trials, daily doses were given up to 600 mg for 8 weeks and 120 mg, for 3 years. No cases of raloxifene overdose were reported during clinical trials.

In adults, symptoms of leg cramps and dizziness have been reported in patients who took more than 120 mg as a single ingestion.

In accidental overdose in children younger than 2 years of age, the maximum reported dose has been 180 mg. In children, symptoms of accidental overdose included ataxia, dizziness, vomiting, rash, diarrhea, tremor, and flushing, and elevation in alkaline phosphatase.

The highest overdose has been approximately 1.5 grams. No fatalities associated with overdose have been reported.

There is no specific antidote for raloxifene hydrochloride.

Shelf life

3 years.

Special precautions for storage

Store in the original package. Do not freeze.

Nature and contents of container

vista tablets are packed either in PVC/PVDC blisters or in high density polyethylene bottles. Blister boxes contain 14, 28, or 84 tablets. Bottles contain 100 tablets.

Not all pack sizes may be marketed in all countries.

Special precautions for disposal and other handling

No special requirements.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.